ClinicalTrials.gg
CompletedNCT04470427Updated Mar 21, 2024Results posted

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

A Phase 3 interventional study of mRNA-1273 and Placebo in SARS-CoV-2, sponsored by ModernaTX, Inc.. Completed at 100 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-21.

Primary conditionCOVID-19Registry: Coronavirus InfectionsReclassifiedWhy we changed it
Registry
Coronavirus Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
COVID-19
Why
  1. The study's title name COVID-19, a narrower term within Coronavirus Infections.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30,415
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 — 2 open to participants now, 5 under way, 1 of them phase 3. 2019-nCoV Vaccine mRNA-1273 · COVID-19.

Enrollment
2nd of 36
30,415 · median 499
Started
2020
with 3 others
Phase 3
10 of 36
none open now
Registered
3rd of 36
by date
Lead sponsor
11 of 36
ModernaTX, Inc.

Among the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, this one is the 2nd largest by enrollment, is one of 4 that started in 2020, is one of 10 in phase 3, and was the 3rd registered.

COVID-19

7,993 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

2 of the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About 2019-nCoV Vaccine mRNA-1273

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, or all of them as a file.
02

Study summary

The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the efficacy, safety, and immunogenicity of mRNA-1273 to prevent COVID-19 for up to 2 years after the second dose of mRNA-1273.

Read the detailed description

This is a 3-part Phase 3 study, with Part A (Blinded Phase), Part B (Open-label Observational Phase), and Part C (Booster Dose Phase). Participants in Part A are blinded to their treatment assignment, with participants receiving either mRNA-1273 vaccine or placebo. Part B of the study is designed to offer participants to be unblinded so that participants who received placebo in Part A can request 2 doses of open-label mRNA-1273 vaccine. Additionally, participants who choose to be unblinded and were only able to receive 1 dose of mRNA-1273 due to administrative reasons, can choose to receive the second dose of mRNA-1273 during Part B. In Part C, a booster dose will be provided for all eligible participants who choose to receive one.

Please access www.modernatx.com/cove-study for additional information, such as Study Overview, Participation, and Site Locations along with contact numbers for each location for the study.

03

Conditions studied

  • SARS-CoV-2

Browse trials for

Keywords

  • mRNA-1273
  • mRNA-1273 vaccine
  • SARS-CoV-2
  • SARS-CoV-2 Vaccine
  • Coronavirus
  • Virus Diseases
  • Messenger RNA
  • COVID-19
  • COVID-19 Vaccine
  • Moderna
04

In context

COVID-19 Reclassified

7,993 studies on the registry are indexed under COVID-19; 468 are open to participants now.

This study's enrollment of 30,415 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.

Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.

Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronavirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (Part A only) Participants who are at high risk of SARS-CoV-2 infection, defined as adults whose locations or circumstances put them at appreciable risk of exposure to SARS-CoV-2 and COVID-19.
  • Understands and agrees to comply with the study procedures and provides written .
  • Able to comply with study procedures based on the assessment of the Investigator.
  • Female participants of non- may be enrolled in the study. Non-childbearing potential is defined as surgically sterile (history of bilateral tubal ligation, bilateral oophorectomy, hysterectomy) or (defined as amenorrhea for ≥12 consecutive months prior to Screening without an alternative medical cause). A follicle-stimulating hormone (FSH) level may be measured at the discretion of the Investigator to confirm postmenopausal status.
  • Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the following criteria:

    • Has a negative pregnancy test at Screening and on the day of the first dose (Day 1, open-label Day 1, and booster dose Day 1).
    • Has practiced adequate or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first dose (Day 1).
    • Has agreed to continue adequate contraception through 3 months following the last dose (Day 29, open-label Day 29, and booster dose Day 1).
    • Is not currently breastfeeding.
  • Healthy adults or adults with pre-existing medical conditions who are in stable condition. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months before enrollment.
  • (Part C Only) Is currently enrolled in Part B of the current study (mRNA-1273-P301).
  • (Part C Only) Has received at least 1 dose of mRNA-1273 in the current study (mRNA-1273-P301).

Exclusion criteria

Exclusion Criteria:

  • Is acutely ill or febrile 72 hours prior to or at Screening or dosing (Part B and Part C). Fever is defined as a body temperature ≥38.0°Celsius/100.4°Fahrenheit. Participants meeting this criterion may be rescheduled within the relevant window periods. Afebrile participants with minor illnesses can be enrolled/dosed at the discretion of the Investigator.
  • Is pregnant or breastfeeding.
  • (Part A Only) Known history of SARS-CoV-2 infection.
  • Prior (Part A) or concurrent (Part B and Part C) administration of non-study coronavirus (SARS-CoV, Middle East Respiratory Syndrome [MERS]-CoV) vaccine or current/planned simultaneous participation in another interventional study to prevent or treat COVID-19.
  • (Part A Only) Demonstrated inability to comply with the study procedures.
  • An immediate family member or household member of this study's personnel.
  • Known or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reaction to the vaccine or its .
  • Bleeding disorder considered a to intramuscular injection or phlebotomy.
  • Has received or plans to receive a vaccine within 28 days prior to the first dose (Day 1) or plans to receive a non-study vaccine within 28 days prior to or after any dose of product (IP) (except for seasonal influenza vaccine).
  • (Part A only) Has participated in an interventional clinical study within 28 days prior to the day of enrollment.
  • or immunodeficient state, including (HIV) infection, asplenia, and recurrent severe infections.
  • Has received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to IP dose administration (for ≥20 milligram (mg)/day of prednisone equivalent).
  • Has received systemic immunoglobulins or blood products within 3 months prior to the day of IP dose administration.
  • Has donated ≥450 milliliters (mL) of blood products within 28 days prior to IP dose administration.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30,415 participants (actual)

Study arms

  • Experimental
    mRNA-1273

    Part A (Blinded): Participants will receive 1 intramuscular (IM) injection of 100 microgram (μg) mRNA-1273 on Day 1 and on Day 29. Part B (Open-label): Participants who receive mRNA-1273-matching placebo during Part A and choose to be unblinded by participating in Part B, will receive 1 IM injection of 100 μg mRNA-1273 on Day 1 and Day 29. Participants who are only able to receive 1 dose of mRNA-1273 due to administrative reasons, will receive 1 IM injection of 100 μg mRNA-1273 on Day 1, if the participant chooses. Part C: Eligible participants in Part B who choose to receive booster dose of mRNA-1273, will receive 1 IM injection of 50 μg mRNA-1273 on Day 1.

    Biological: mRNA-1273 · Biological: Placebo

  • Placebo comparator
    Placebo

    Part A only: Participants will receive 1 IM injection of mRNA-1273-matching placebo on Day 1 and on Day 29, if the participant chooses.

    Biological: Placebo

Interventions

  • BiologicalmRNA-1273

    Sterile liquid for injection

  • BiologicalPlacebo

    0.9% sodium chloride (normal saline) injection

07

What researchers measure

Primary outcomes

  1. Part A: Number of Participants With a First Occurrence of COVID-19 Starting 14 Days After Second Dose

    COVID-19 cases were defined as participants meeting clinical criteria based both on symptoms for COVID-19 and on RT-PCR detection of SARS-CoV-2 from samples collected within 72 hours of the study participant reporting symptoms that met the definition of COVID-19. An adjudication committee was assembled for the purpose of reviewing potential cases to determine if the criteria for COVID-19 were met.

    Time frame: From Day 43 (14 days after second dose) up to approximately 7 months after the second dose

  2. Part A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) After First Dose

    Solicited ARs (local and systemic) were collected in electronic diary (eDiary) within 7 days of dosing. Local ARs included: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, body temperature (potentially fever), and chills. Severity grading for solicited ARs is based on modified Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventative Vaccine Clinical Trials. Severity was graded 0-4; a lower score indicated lower severity and a higher score indicated greater severity. The Investigator determined if solicited AR was also to be recorded as an AE. Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is in Reported "Adverse Events" section.

    Time frame: up to Day 7 (7 days after first dose)

  3. Part A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) After Second Dose

    Solicited ARs (local and systemic) were collected in eDiary within 7 days of dosing. Local ARs included: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, body temperature (potentially fever), and chills. Severity grading for solicited ARs is based on modified Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventative Vaccine Clinical Trials. Severity was graded 0-4; lower score indicated lower severity and a higher score indicated greater severity. The Investigator determined if solicited AR was also to be recorded as an AE. Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is in Reported "Adverse Events" section

    Time frame: Day 29 to Day 35 (from second dose to 7 days after second dose)

  4. Parts A and B: Number of Participants With Medically Attended AEs (MAAEs) and AEs Leading to Discontinuation

    An MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner (HCP). A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

    Time frame: Day 1 (after dosing) through end of study (up to Day 759)

  5. Parts A and B: Number of Participants With Serious AEs (SAEs)

    An SAE was defined as any AE that resulted in death, is life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

    Time frame: Day 1 (after dosing) through end of study (up to Day 759)

Secondary outcomes

  1. Part A: Number of Participants With Unsolicited AEs up to 28 Days After Any Injection Dose

    Unsolicited AE was any AE reported by the participant that was not specified as an AR or was specified as a solicited AR in the protocol but started outside the protocol-defined, post-injection period for reporting solicited ARs. Unsolicited AEs were collected for the 28 days after any injection. An AE was as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A summary of all SAEs and all nonserious AEs ("Other") reported up to the end of the study, regardless of causality, is located in the Reported "Adverse Events" section.

    Time frame: Up to 28 days after any dose

  2. Parts A and B: Number of Participants With a First Occurrence of Severe COVID-19 Starting 14 Days After Second Dose

    COVID-19 cases were defined as participants meeting clinical criteria based on symptoms for COVID-19 and reverse transcriptase polymerase chain reaction (RT-PCR) detection of SARS-CoV-2 from samples collected within 72 hours of the participant reporting symptoms meeting the definition of COVID-19. An adjudication committee reviewed potential cases to determine if the criteria for COVID-19 were met. Clinical signs indicative of severe COVID-19 systemic illness included any of the following: respiratory rate ≥30 per minute, heart rate ≥125 beats per minute, oxygen saturation (SpO2) ≤93% on room air at sea level, or partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FIO2) \<300 millimeter of mercury (mm Hg), or respiratory failure or acute respiratory distress syndrome (ARDS), evidence of shock, or significant acute renal, hepatic, or neurologic dysfunction, or admission to an intensive care unit or death.

    Time frame: From Day 43 (14 days after second dose) up to approximately 8 months for Part A and from PDV/unblinding (at 4 months) to up to 8 months for Part B

  3. Part A: Number of Participants With a First Occurrence of Either COVID-19 or SARS-CoV-2 Infection Regardless of Symptomatology or Severity Starting 14 Days After Second Dose

    COVID-19 cases were defined as participants meeting clinical criteria based both on symptoms for COVID-19 and on RT-PCR detection of SARS-CoV-2 from samples collected within 72 hours of the study participant reporting symptoms that met the definition of COVID-19. An adjudication committee was assembled for the purpose of reviewing potential cases to determine if the criteria for COVID-19 were met. SARS-CoV-2 infection was defined by seroconversion due to infection measured by binding antibody (bAb) levels against SARS-CoV-2 nucleocapsid or by positive RT-PCR at predefined timepoints. Seroconversion was defined by the participant's serostatus at baseline.

    Time frame: From Day 43 (14 days after second dose) up to approximately 7 months after the second dose

  4. Part A: Number of Participants With a Secondary Case Definition of COVID-19 Starting 14 Days After Second Dose

    Secondary case definition of COVID-19 was defined as the presence of at least 1 of the following systemic symptoms: fever (temperature ≥38ºC), or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle aches or body aches, headache, new loss of taste or smell, sore throat, nasal congestion or rhinorrhea, nausea or vomiting, or diarrhea and a positive nasopharyngeal swab, nasal swab, or saliva sample (or respiratory sample, if hospitalized) for SARS-CoV-2 by RT-PCR.

    Time frame: From Day 43 (14 days after second dose) up to approximately 7 months after the second dose

  5. Parts A and B: Number of Participants Who Died Due to a Cause Directly Attributed to a Complication of COVID-19 Starting 14 Days After Second Dose

    Time frame: From Day 43 (14 days after second dose) up to approximately 8 months for Part A and from PDV/unblinding (at 4 months) to up to 8 months for Part B

  6. Part A: Number of Participants With a First Occurrence of COVID-19 Starting 14 Days After First Dose

    COVID-19 cases were defined as participants meeting clinical criteria based both on symptoms for COVID-19 and on RT-PCR detection of SARS-CoV-2 from samples collected within 72 hours of the study participant reporting symptoms that met the definition of COVID-19. An adjudication committee was assembled for the purpose of reviewing potential cases to determine if the criteria for COVID-19 were met.

    Time frame: From 14 days after first dose up to approximately 8 months

  7. Part A: Number of Participants With a First Occurrence of COVID-19 Starting 14 Days After Second Dose Regardless of Evidence of Prior SARS-CoV-2 Infection

    COVID-19 cases were defined as participants meeting clinical criteria based both on symptoms for COVID-19 and on RT-PCR detection of SARS-CoV-2 from samples collected within 72 hours of the study participant reporting symptoms that met the definition of COVID-19. An adjudication committee was assembled for the purpose of reviewing potential cases to determine if the criteria for COVID-19 were met.

    Time frame: From Day 43 (14 days after second dose) up to approximately 7 months after the second dose

  8. Part A: Number of Participants With a First Occurrence of SARS-CoV-2 Infection in the Absence of Symptoms Defining COVID-19 Starting 14 Days After Second Dose

    SARS-CoV-2 infection was defined by seroconversion due to infection measured by binding antibody (bAb) levels against SARS-CoV-2 nucleocapsid or by positive RT-PCR at predefined timepoints. Seroconversion was defined by the participant's serostatus at baseline.

    Time frame: From Day 43 (14 days after second dose) up to approximately 7 months after the second dose

  9. Part A: Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (nAb)

    GMT (50% inhibitory dose \[ID50\], 80% inhibitory dose \[ID80\]) of nAb against SARS-CoV-2 pseudotyped viruses as measured by pseudovirus nAb assay is reported. 95% CI was based on the t-distribution of log-transformed values for GM titer, then back transformed to original scale for presentation. Baseline SARS-CoV-2 Status: Positive if there is immunologic or virologic evidence of prior COVID-19, defined as positive RT-PCR test or positive Elecsys result at Day 1. Negative is defined as negative RT-PCR test and negative Elecsys result at Day 1.

    Time frame: Day 1, Day 29, Day 57

  10. Part A: Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Specific nAb

    The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. 95% CI was calculated based on the difference in the log-transformed values for GMFR, then back transformed to the original scale for presentation. GMFR for ID50 and ID80 neutralizing antibodies against SARS-CoV-2 S-protein, as measured by pseudovirus neutralizing antibody is presented. Baseline SARS-CoV-2 Status: Positive if there is immunologic or virologic evidence of prior COVID-19, defined as positive RT-PCR test or positive Elecsys result at Day 1. Negative is defined as negative RT-PCR test and negative Elecsys result at Day 1

    Time frame: Day 29, Day 57

  11. Part A: Percentage of Participants With Seroresponse Against SARS-CoV-2

    Seroresponse to pseudovirus neutralizing antibody ID50 titer at a participant level is defined as a change from below the LLOQ to equal or above the LLOQ, or at least a 3.3-fold rise if baseline is equal to or above the LLOQ. Seroresponse to pseudovirus neutralizing antibody ID80 titer at a participant level is defined as a change from below the LLOQ to equal or above the LLOQ, or at least a 2.3-fold rise if baseline is equal to or above the LLOQ. Baseline SARS-CoV-2 Status: Positive if there is immunologic or virologic evidence of prior COVID-19, defined as positive RT-PCR test or positive Elecsys result at Day 1. Negative is defined as negative RT-PCR test and negative Elecsys result at Day 1.

    Time frame: Day 29, Day 57

  12. Part C: GMT of SARS-CoV-2 Specific nAb Measured by Pseudovirus (VAC62)

    95% CI is calculated based on the t-distribution of the log-transformed values for GM value, then back transformed to the original scale for presentation.

    Time frame: Pre-booster (Baseline), post-booster Day 29 and post-booster Day 181

  13. Part C: Percentage of Participants With Seroresponse Against SARS-CoV-2 Measured by Pseudovirus (VAC62)

    Pseudovirus neutralizing antibody (VAC62) from pre-booster is presented. Seroresponse at a participant level is defined as a change from below the LLOQ to \>= 4 x LLOQ, or at least a 4-fold rise if pre-booster is equal to or above the LLOQ.

    Time frame: Post-booster Day 29 and post-booster Day 181

  14. Part C: Geometric Mean Concentration (GMC) of SARS-CoV-2 Specific nAb After BD Compared to After Second Dose in Part A Measured by Pseudovirus (VAC62)

    95% CI is calculated based on the t-distribution of the log-transformed values for GMC, then back transformed to the original scale for presentation.

    Time frame: Part C BD Day 29 and Part A Day 57

  15. Part C: Percentage of Participants With Seroresponse Against SARS-CoV-2 After BD Compared to After Second Dose in Part A

    Pseudovirus neutralizing antibody (VAC62) are presented. Seroresponse at a participant level is defined as a change from below the LLOQ to equal or above 4 x LLOQ, or at least a4-fold rise if baseline (Pre- Dose 1) is equal to or above the LLOQ.

    Time frame: Part C BD Day 29 and Part A Day 57

08

Results

Posted Mar 21, 2024

Participant flow

Part A: Blinded
Participant flow — Part A: Blinded
MilestonePart A (Blinded): PlaceboPart A (Blinded): mRNA-1273Part B (Open-label): PlaceboPart B (Open-label): Placebo/mRNA-1273Part B (Open-label): mRNA-1273Part C: mRNA-1273 Booster
Started15206152090000
Received any study injection15166151800000
Per-protocol (pp) set:14164142870000
Per-protocol random subcohort for immunogenicity (pprsi)27211850000
Solicited safety set15159151790000
Safety set15162151840000
Full analysis set15166151800000
Completed14375146610000
Not completed8315480000
Withdrew: Discontinued from study in part a8315480000
Part B :Open-label
Participant flow — Part B :Open-label
MilestonePart A (Blinded): PlaceboPart A (Blinded): mRNA-1273Part B (Open-label): PlaceboPart B (Open-label): Placebo/mRNA-1273Part B (Open-label): mRNA-1273Part C: mRNA-1273 Booster
Started00251312649151840
Safety set00251312649151840
Pp set00210412060142870
Participants who had pdv/unblinding) and had the option to receive booster dose in part c00172512649146610
Completed0014910464101710
Not completed002364218550130
Withdrew: Other than specified0078805230
Withdrew: Discontinued from study in part b001576218544900
Part C: Booster
Participant flow — Part C: Booster
MilestonePart A (Blinded): PlaceboPart A (Blinded): mRNA-1273Part B (Open-label): PlaceboPart B (Open-label): Placebo/mRNA-1273Part B (Open-label): mRNA-1273Part C: mRNA-1273 Booster
Started0000019609
Pp set0000016368
Pp immunogenicity subset (ppis)00000731
Ppis-negative (neg)00000682
Completed0000016691
Not completed000002918
Withdrew: Discontinued from study in part c000002918

Outcome measures

PrimaryPart A: Number of Participants With a First Occurrence of COVID-19 Starting 14 Days After Second Dose

COVID-19 cases were defined as participants meeting clinical criteria based both on symptoms for COVID-19 and on RT-PCR detection of SARS-CoV-2 from samples collected within 72 hours of the study participant reporting symptoms that met the definition of COVID-19. An adjudication committee was assembled for the purpose of reviewing potential cases to determine if the criteria for COVID-19 were met.

Time frame:
From Day 43 (14 days after second dose) up to approximately 7 months after the second dose
Reported as:
Count of participants · Participants
Part A: Number of Participants With a First Occurrence of COVID-19 Starting 14 Days After Second Dose
ParticipantsPart A (Blinded): PlaceboPart A (Blinded): mRNA-1273
Part A: Number of Participants With a First Occurrence of COVID-19 Starting 14 Days After Second Dose74455
Statistical analysis
  • Part A (Blinded): Placebo vs Part A (Blinded): mRNA-1273 · Vaccine Efficacy (VE) · p = <.0001 · Ve: 93.2 · 95% CI 91.0 to 94.8VE (percent) was estimated with 1 - Hazard Ratio (mRNA-1273 vs. placebo) from stratified Cox proportional hazard model.
PrimaryPart A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) After First Dose

Solicited ARs (local and systemic) were collected in electronic diary (eDiary) within 7 days of dosing. Local ARs included: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, body temperature (potentially fever), and chills. Severity grading for solicited ARs is based on modified Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventative Vaccine Clinical Trials. Severity was graded 0-4; a lower score indicated lower severity and a higher score indicated greater severity. The Investigator determined if solicited AR was also to be recorded as an AE. Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is in Reported "Adverse Events" section.

Time frame:
up to Day 7 (7 days after first dose)
Reported as:
Count of participants · Participants
Part A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) After First Dose
ParticipantsPart A (Blinded): PlaceboPart A (Blinded): mRNA-1273
Grade 151349329
Grade 217823134
Grade 3363849
Grade 465
PrimaryPart A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) After Second Dose

Solicited ARs (local and systemic) were collected in eDiary within 7 days of dosing. Local ARs included: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, body temperature (potentially fever), and chills. Severity grading for solicited ARs is based on modified Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventative Vaccine Clinical Trials. Severity was graded 0-4; lower score indicated lower severity and a higher score indicated greater severity. The Investigator determined if solicited AR was also to be recorded as an AE. Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is in Reported "Adverse Events" section

Time frame:
Day 29 to Day 35 (from second dose to 7 days after second dose)
Reported as:
Count of participants · Participants
Part A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) After Second Dose
ParticipantsPart A (Blinded): PlaceboPart A (Blinded): mRNA-1273
Grade 143464847
Grade 215585800
Grade 33482895
Grade 4314
PrimaryParts A and B: Number of Participants With Medically Attended AEs (MAAEs) and AEs Leading to Discontinuation

An MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner (HCP). A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

Time frame:
Day 1 (after dosing) through end of study (up to Day 759)
Reported as:
Count of participants · Participants
Parts A and B: Number of Participants With Medically Attended AEs (MAAEs) and AEs Leading to Discontinuation
ParticipantsPart A (Blinded): PlaceboPart A (Blinded): mRNA-1273Part B (Open-label): PlaceboPart B (Open-label): Placebo/mRNA-1273Part B (Open-label): mRNA-1273
MAAEs4561392110955135809
AEs Leading to Discontinuation252733035
PrimaryParts A and B: Number of Participants With Serious AEs (SAEs)

An SAE was defined as any AE that resulted in death, is life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

Time frame:
Day 1 (after dosing) through end of study (up to Day 759)
Reported as:
Count of participants · Participants
Parts A and B: Number of Participants With Serious AEs (SAEs)
ParticipantsPart A (Blinded): PlaceboPart A (Blinded): mRNA-1273Part B (Open-label): PlaceboPart B (Open-label): Placebo/mRNA-1273Part B (Open-label): mRNA-1273
Parts A and B: Number of Participants With Serious AEs (SAEs)30829215536516
SecondaryPart A: Number of Participants With Unsolicited AEs up to 28 Days After Any Injection Dose

Unsolicited AE was any AE reported by the participant that was not specified as an AR or was specified as a solicited AR in the protocol but started outside the protocol-defined, post-injection period for reporting solicited ARs. Unsolicited AEs were collected for the 28 days after any injection. An AE was as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A summary of all SAEs and all nonserious AEs ("Other") reported up to the end of the study, regardless of causality, is located in the Reported "Adverse Events" section.

Time frame:
Up to 28 days after any dose
Reported as:
Count of participants · Participants
Part A: Number of Participants With Unsolicited AEs up to 28 Days After Any Injection Dose
ParticipantsPart A (Blinded): PlaceboPart A (Blinded): mRNA-1273
Part A: Number of Participants With Unsolicited AEs up to 28 Days After Any Injection Dose43384752
SecondaryParts A and B: Number of Participants With a First Occurrence of Severe COVID-19 Starting 14 Days After Second Dose

COVID-19 cases were defined as participants meeting clinical criteria based on symptoms for COVID-19 and reverse transcriptase polymerase chain reaction (RT-PCR) detection of SARS-CoV-2 from samples collected within 72 hours of the participant reporting symptoms meeting the definition of COVID-19. An adjudication committee reviewed potential cases to determine if the criteria for COVID-19 were met. Clinical signs indicative of severe COVID-19 systemic illness included any of the following: respiratory rate ≥30 per minute, heart rate ≥125 beats per minute, oxygen saturation (SpO2) ≤93% on room air at sea level, or partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FIO2) \<300 millimeter of mercury (mm Hg), or respiratory failure or acute respiratory distress syndrome (ARDS), evidence of shock, or significant acute renal, hepatic, or neurologic dysfunction, or admission to an intensive care unit or death.

Time frame:
From Day 43 (14 days after second dose) up to approximately 8 months for Part A and from PDV/unblinding (at 4 months) to up to 8 months for Part B
Reported as:
Count of participants · Participants
Parts A and B: Number of Participants With a First Occurrence of Severe COVID-19 Starting 14 Days After Second Dose
ParticipantsPart A (Blinded): PlaceboPart A (Blinded): mRNA-1273Part B (Open-label): PlaceboPart B (Open-label): Placebo/mRNA-1273Part B (Open-label): mRNA-1273
Parts A and B: Number of Participants With a First Occurrence of Severe COVID-19 Starting 14 Days After Second Dose1062181
Statistical analysis
  • Part A (Blinded): Placebo vs Part A (Blinded): mRNA-1273 · VE · Ve: 98.2 · 95% CI 92.8 to 99.6VE (percent) was estimated with 1 - Hazard Ratio (mRNA-1273 vs. placebo) from stratified Cox proportional hazard model.
SecondaryPart A: Number of Participants With a First Occurrence of Either COVID-19 or SARS-CoV-2 Infection Regardless of Symptomatology or Severity Starting 14 Days After Second Dose

COVID-19 cases were defined as participants meeting clinical criteria based both on symptoms for COVID-19 and on RT-PCR detection of SARS-CoV-2 from samples collected within 72 hours of the study participant reporting symptoms that met the definition of COVID-19. An adjudication committee was assembled for the purpose of reviewing potential cases to determine if the criteria for COVID-19 were met. SARS-CoV-2 infection was defined by seroconversion due to infection measured by binding antibody (bAb) levels against SARS-CoV-2 nucleocapsid or by positive RT-PCR at predefined timepoints. Seroconversion was defined by the participant's serostatus at baseline.

Time frame:
From Day 43 (14 days after second dose) up to approximately 7 months after the second dose
Reported as:
Count of participants · Participants
Part A: Number of Participants With a First Occurrence of Either COVID-19 or SARS-CoV-2 Infection Regardless of Symptomatology or Severity Starting 14 Days After Second Dose
ParticipantsPart A (Blinded): PlaceboPart A (Blinded): mRNA-1273
Part A: Number of Participants With a First Occurrence of Either COVID-19 or SARS-CoV-2 Infection Regardless of Symptomatology or Severity Starting 14 Days After Second Dose1339280
Statistical analysis
  • Part A (Blinded): Placebo vs Part A (Blinded): mRNA-1273 · Ve: 82.0 · 95% CI 79.5 to 84.2VE (percent) was estimated with 1 - Hazard Ratio (mRNA-1273 vs. placebo) from stratified Cox proportional hazard model
SecondaryPart A: Number of Participants With a Secondary Case Definition of COVID-19 Starting 14 Days After Second Dose

Secondary case definition of COVID-19 was defined as the presence of at least 1 of the following systemic symptoms: fever (temperature ≥38ºC), or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle aches or body aches, headache, new loss of taste or smell, sore throat, nasal congestion or rhinorrhea, nausea or vomiting, or diarrhea and a positive nasopharyngeal swab, nasal swab, or saliva sample (or respiratory sample, if hospitalized) for SARS-CoV-2 by RT-PCR.

Time frame:
From Day 43 (14 days after second dose) up to approximately 7 months after the second dose
Reported as:
Count of participants · Participants
Part A: Number of Participants With a Secondary Case Definition of COVID-19 Starting 14 Days After Second Dose
ParticipantsPart A (Blinded): PlaceboPart A (Blinded): mRNA-1273
Part A: Number of Participants With a Secondary Case Definition of COVID-19 Starting 14 Days After Second Dose80758
Statistical analysis
  • Part A (Blinded): Placebo vs Part A (Blinded): mRNA-1273 · Ve: 93.4 · 95% CI 91.4 to 94.9VE (percent) was estimated with 1 - Hazard Ratio (mRNA-1273 vs. placebo) from stratified Cox proportional hazard model.
SecondaryParts A and B: Number of Participants Who Died Due to a Cause Directly Attributed to a Complication of COVID-19 Starting 14 Days After Second Dose
Time frame:
From Day 43 (14 days after second dose) up to approximately 8 months for Part A and from PDV/unblinding (at 4 months) to up to 8 months for Part B
Reported as:
Count of participants · Participants
Parts A and B: Number of Participants Who Died Due to a Cause Directly Attributed to a Complication of COVID-19 Starting 14 Days After Second Dose
ParticipantsPart A (Blinded): PlaceboPart A (Blinded): mRNA-1273Part B (Open-label): PlaceboPart B (Open-label): Placebo/mRNA-1273Part B (Open-label): mRNA-1273
Parts A and B: Number of Participants Who Died Due to a Cause Directly Attributed to a Complication of COVID-19 Starting 14 Days After Second Dose30000
SecondaryPart A: Number of Participants With a First Occurrence of COVID-19 Starting 14 Days After First Dose

COVID-19 cases were defined as participants meeting clinical criteria based both on symptoms for COVID-19 and on RT-PCR detection of SARS-CoV-2 from samples collected within 72 hours of the study participant reporting symptoms that met the definition of COVID-19. An adjudication committee was assembled for the purpose of reviewing potential cases to determine if the criteria for COVID-19 were met.

Time frame:
From 14 days after first dose up to approximately 8 months
Reported as:
Count of participants · Participants
Part A: Number of Participants With a First Occurrence of COVID-19 Starting 14 Days After First Dose
ParticipantsPart A (Blinded): PlaceboPart A (Blinded): mRNA-1273
Part A: Number of Participants With a First Occurrence of COVID-19 Starting 14 Days After First Dose76956
Statistical analysis
  • Part A (Blinded): Placebo vs Part A (Blinded): mRNA-1273 · Ve: 93.3 · 95% CI 91.1 to 94.9VE (percent) was estimated with 1 - Hazard Ratio (mRNA-1273 vs. placebo) from stratified Cox proportional hazard model.
SecondaryPart A: Number of Participants With a First Occurrence of COVID-19 Starting 14 Days After Second Dose Regardless of Evidence of Prior SARS-CoV-2 Infection

COVID-19 cases were defined as participants meeting clinical criteria based both on symptoms for COVID-19 and on RT-PCR detection of SARS-CoV-2 from samples collected within 72 hours of the study participant reporting symptoms that met the definition of COVID-19. An adjudication committee was assembled for the purpose of reviewing potential cases to determine if the criteria for COVID-19 were met.

Time frame:
From Day 43 (14 days after second dose) up to approximately 7 months after the second dose
Reported as:
Count of participants · Participants
Part A: Number of Participants With a First Occurrence of COVID-19 Starting 14 Days After Second Dose Regardless of Evidence of Prior SARS-CoV-2 Infection
ParticipantsPart A (Blinded): PlaceboPart A (Blinded): mRNA-1273
Part A: Number of Participants With a First Occurrence of COVID-19 Starting 14 Days After Second Dose Regardless of Evidence of Prior SARS-CoV-2 Infection75458
Statistical analysis
  • Part A (Blinded): Placebo vs Part A (Blinded): mRNA-1273 · Ve: 82.0 · 95% CI 79.5 to 84.3VE (percent) was estimated with 1 - Hazard Ratio (mRNA-1273 vs. placebo) from stratified Cox proportional hazard model.
SecondaryPart A: Number of Participants With a First Occurrence of SARS-CoV-2 Infection in the Absence of Symptoms Defining COVID-19 Starting 14 Days After Second Dose

SARS-CoV-2 infection was defined by seroconversion due to infection measured by binding antibody (bAb) levels against SARS-CoV-2 nucleocapsid or by positive RT-PCR at predefined timepoints. Seroconversion was defined by the participant's serostatus at baseline.

Time frame:
From Day 43 (14 days after second dose) up to approximately 7 months after the second dose
Reported as:
Count of participants · Participants
Part A: Number of Participants With a First Occurrence of SARS-CoV-2 Infection in the Absence of Symptoms Defining COVID-19 Starting 14 Days After Second Dose
ParticipantsPart A (Blinded): PlaceboPart A (Blinded): mRNA-1273
Part A: Number of Participants With a First Occurrence of SARS-CoV-2 Infection in the Absence of Symptoms Defining COVID-19 Starting 14 Days After Second Dose498214
Statistical analysis
  • Part A (Blinded): Placebo vs Part A (Blinded): mRNA-1273 · Ve: 63.0 · 95% CI 56.6 to 68.5VE (percent) was estimated with 1 - Hazard Ratio (mRNA-1273 vs. placebo) from stratified Cox proportional hazard model.
SecondaryPart A: Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (nAb)

GMT (50% inhibitory dose \[ID50\], 80% inhibitory dose \[ID80\]) of nAb against SARS-CoV-2 pseudotyped viruses as measured by pseudovirus nAb assay is reported. 95% CI was based on the t-distribution of log-transformed values for GM titer, then back transformed to original scale for presentation. Baseline SARS-CoV-2 Status: Positive if there is immunologic or virologic evidence of prior COVID-19, defined as positive RT-PCR test or positive Elecsys result at Day 1. Negative is defined as negative RT-PCR test and negative Elecsys result at Day 1.

Time frame:
Day 1, Day 29, Day 57
Reported as:
Geometric mean · Titer
Part A: Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (nAb)
TiterPart A (Blinded): PlaceboPart A (Blinded): mRNA-1273
Baseline SARS-CoV-2 Negative, ID50, Day 1NA (NA to NA)9.624 (9.35 to 9.90)
Baseline SARS-CoV-2 Negative', ID50, Day 299.515 (9.00 to 10.06)54.866 (50.98 to 59.04)
Baseline SARS-CoV-2 Negative', ID50, Day 579.903 (8.99 to 10.90)1081.124 (1019.80 to 1146.14)
Baseline SARS-CoV-2 Negative', ID80, Day 1NA (NA to NA)7.332 (7.18 to 7.49)
Baseline SARS-CoV-2 Negative', ID80, Day 297.279 (7.03 to 7.54)19.684 (18.55 to 20.89)
Baseline SARS-CoV-2 Negative', ID80, Day 577.522 (7.00 to 8.09)334.867 (317.84 to 352.81)
Baseline SARS-CoV-2 Positive, ID50, Day 182.519 (59.40 to 114.64)68.117 (49.88 to 93.02)
Baseline SARS-CoV-2 Positive, ID50, Day 2952.728 (39.45 to 70.48)1478.910 (1069.60 to 2044.86)
Baseline SARS-CoV-2 Positive, ID50, Day 5747.708 (35.41 to 64.28)3145.904 (2539.80 to 3896.66)
Baseline SARS-CoV-2 Positive, ID80, Day 129.580 (22.39 to 39.09)24.996 (19.12 to 32.68)
Baseline SARS-CoV-2 Positive, ID80, Day 2920.994 (16.42 to 26.84)518.388 (380.39 to 706.44)
Baseline SARS-CoV-2 Positive, ID80, Day 5719.228 (15.03 to 24.60)1099.847 (903.83 to 1338.37)
SecondaryPart A: Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Specific nAb

The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. 95% CI was calculated based on the difference in the log-transformed values for GMFR, then back transformed to the original scale for presentation. GMFR for ID50 and ID80 neutralizing antibodies against SARS-CoV-2 S-protein, as measured by pseudovirus neutralizing antibody is presented. Baseline SARS-CoV-2 Status: Positive if there is immunologic or virologic evidence of prior COVID-19, defined as positive RT-PCR test or positive Elecsys result at Day 1. Negative is defined as negative RT-PCR test and negative Elecsys result at Day 1

Time frame:
Day 29, Day 57
Reported as:
Geometric mean · Ratio
Part A: Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Specific nAb
RatioPart A (Blinded): PlaceboPart A (Blinded): mRNA-1273
Baseline SARS-CoV-2 Negative, ID50 Day 291.03 (0.97 to 1.09)5.69 (5.29 to 6.12)
Baseline SARS-CoV-2 Negative, ID50 Day 571.07 (0.97 to 1.18)112.30 (105.42 to 119.62)
Baseline SARS-CoV-2, Negative, ID80 Day 291.02 (0.98 to 1.05)2.68 (2.53 to 2.84)
Baseline SARS-CoV-2 Negative, ID80 Day 571.05 (0.98 to 1.13)45.62 (43.21 to 48.17)
Baseline SARS-CoV-2, Positive, ID50 Day 290.64 (0.56 to 0.73)21.71 (16.08 to 29.32)
Baseline SARS-CoV-2 Positive, ID50 Day 570.59 (0.50 to 0.69)46.18 (34.10 to 62.55)
Baseline SARS-CoV-2 Positive, ID80 Day 290.71 (0.64 to 0.79)20.74 (15.30 to 28.10)
Baseline SARS-CoV-2 Positive, ID80 Day 570.66 (0.57 to 0.75)44.00 (33.99 to 56.97)
SecondaryPart A: Percentage of Participants With Seroresponse Against SARS-CoV-2

Seroresponse to pseudovirus neutralizing antibody ID50 titer at a participant level is defined as a change from below the LLOQ to equal or above the LLOQ, or at least a 3.3-fold rise if baseline is equal to or above the LLOQ. Seroresponse to pseudovirus neutralizing antibody ID80 titer at a participant level is defined as a change from below the LLOQ to equal or above the LLOQ, or at least a 2.3-fold rise if baseline is equal to or above the LLOQ. Baseline SARS-CoV-2 Status: Positive if there is immunologic or virologic evidence of prior COVID-19, defined as positive RT-PCR test or positive Elecsys result at Day 1. Negative is defined as negative RT-PCR test and negative Elecsys result at Day 1.

Time frame:
Day 29, Day 57
Reported as:
Number · percentage of participants
Part A: Percentage of Participants With Seroresponse Against SARS-CoV-2
percentage of participantsPart A (Blinded): PlaceboPart A (Blinded): mRNA-1273
Baseline SARS-CoV-2 Negative, ID50, Day 290.7 (0.0 to 3.9)81.4 (78.9 to 83.7)
Baseline SARS-CoV-2 Negative, ID50, Day 571.4 (0.2 to 5.0)98.9 (98.0 to 99.4)
Baseline SARS-CoV-2 Negative, ID80, Day 290.7 (0.0 to 3.9)63.0 (60.0 to 65.9)
Baseline SARS-CoV-2 Negative, ID80, Day 571.4 (0.2 to 5.0)98.9 (98.0 to 99.4)
Baseline SARS-CoV-2 Positive, ID50, Day 290.8 (0.0 to 4.3)87.7 (80.8 to 92.8)
Baseline SARS-CoV-2 Positive, ID50, Day 571.6 (0.2 to 5.5)94.6 (89.2 to 97.8)
Baseline SARS-CoV-2 Positive, ID80, Day 293.1 (0.9 to 7.8)90.0 (83.5 to 94.6)
Baseline SARS-CoV-2 Positive, ID80, Day 572.3 (0.5 to 6.6)96.2 (91.3 to 98.7)
SecondaryPart C: GMT of SARS-CoV-2 Specific nAb Measured by Pseudovirus (VAC62)

95% CI is calculated based on the t-distribution of the log-transformed values for GM value, then back transformed to the original scale for presentation.

Time frame:
Pre-booster (Baseline), post-booster Day 29 and post-booster Day 181
Reported as:
Geometric mean · Titer
Part C: GMT of SARS-CoV-2 Specific nAb Measured by Pseudovirus (VAC62)
TiterPart C (Booster): mRNA-1273 Booster
Pre-booster (Baseline)163.848 (147.977 to 181.421)
BD Day 298122.189 (7603.021 to 8676.808)
BD Day 1812951.123 (2701.648 to 3223.636)
SecondaryPart C: Percentage of Participants With Seroresponse Against SARS-CoV-2 Measured by Pseudovirus (VAC62)

Pseudovirus neutralizing antibody (VAC62) from pre-booster is presented. Seroresponse at a participant level is defined as a change from below the LLOQ to \>= 4 x LLOQ, or at least a 4-fold rise if pre-booster is equal to or above the LLOQ.

Time frame:
Post-booster Day 29 and post-booster Day 181
Reported as:
Number · percentage of participants
Part C: Percentage of Participants With Seroresponse Against SARS-CoV-2 Measured by Pseudovirus (VAC62)
percentage of participantsPart C (Booster): mRNA-1273 Booster
BD Day 2994.5 (92.5 to 96.1)
BD Day 18189.2 (86.4 to 91.6)
SecondaryPart C: Geometric Mean Concentration (GMC) of SARS-CoV-2 Specific nAb After BD Compared to After Second Dose in Part A Measured by Pseudovirus (VAC62)

95% CI is calculated based on the t-distribution of the log-transformed values for GMC, then back transformed to the original scale for presentation.

Time frame:
Part C BD Day 29 and Part A Day 57
Reported as:
Geometric mean · arbitrary units (AU)/milliliters (mL)
Part C: Geometric Mean Concentration (GMC) of SARS-CoV-2 Specific nAb After BD Compared to After Second Dose in Part A Measured by Pseudovirus (VAC62)
arbitrary units (AU)/milliliters (mL)Part C (Booster): mRNA-1273 BoosterPart A mRNA-1273
Part C BD Day 297739.680 (7240.926 to 8272.789)—
Part A Day 57—1111.274 (1041.684 to 1185.513)
Statistical analysis
  • Part C (Booster): mRNA-1273 Booster vs Part A mRNA-1273 · Ratio of gmc: 6.996 · 95% CI 6.509 to 7.520
SecondaryPart C: Percentage of Participants With Seroresponse Against SARS-CoV-2 After BD Compared to After Second Dose in Part A

Pseudovirus neutralizing antibody (VAC62) are presented. Seroresponse at a participant level is defined as a change from below the LLOQ to equal or above 4 x LLOQ, or at least a4-fold rise if baseline (Pre- Dose 1) is equal to or above the LLOQ.

Time frame:
Part C BD Day 29 and Part A Day 57
Reported as:
Number · percentage of participants
Part C: Percentage of Participants With Seroresponse Against SARS-CoV-2 After BD Compared to After Second Dose in Part A
percentage of participantsPart C (Booster): mRNA-1273 BoosterPart A mRNA-1273
Part C BD Day 29100 (99.4 to 100)—
Part A Day 57—98.8 (97.7 to 99.5)
Statistical analysis
  • Part C (Booster): mRNA-1273 Booster vs Part A mRNA-1273 · Difference in seroresponse: 0.9 · 95% CI 0.1 to 1.895% CI were calculated using adjusted Wald method for the paired binary data.

Adverse events

Collected over up to Day 759 (end of study). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A (Blinded): Placebo18/15,206 (0.1%)308/15,162 (2%)2,783/15,162 (18.4%)
Part A (Blinded): mRNA-127316/15,209 (0.1%)292/15,184 (1.9%)2,247/15,184 (14.8%)
Part B (Open-label): Placebo2/2,513 (0.1%)15/2,513 (0.6%)42/2,513 (1.7%)
Part B (Open-label): Placebo/mRNA-127323/12,649 (0.2%)536/12,649 (4.2%)1,739/12,649 (13.7%)
Part B (Open-label): mRNA-127335/15,184 (0.2%)516/15,184 (3.4%)1,404/15,184 (9.2%)
Part C: mRNA-1273 Booster52/19,609 (0.3%)755/19,609 (3.9%)8,277/19,609 (42.2%)
Most frequent serious events
Showing 10 of 944
Most frequent serious events
EventPart A (Blinded): PlaceboPart A (Blinded): mRNA-1273Part B (Open-label): PlaceboPart B (Open-label): Placebo/mRNA-1273Part B (Open-label): mRNA-1273Part C: mRNA-1273 Booster
Cardiac disordersEar and labyrinth disorders45/1516244/151842/251385/1264981/15184142/19609
OsteoarthritisMusculoskeletal and connective tissue disorders19/1516212/151841/251330/1264921/1518421/19609
COVID-19Infections and infestations33/151621/151842/251310/126496/151848/19609
PneumoniaInfections and infestations11/151629/151841/251325/1264913/1518419/19609
Atrial fibrillationEar and labyrinth disorders11/151627/151840/251311/1264913/1518427/19609
SepsisInfections and infestations4/151624/151840/251316/126499/151847/19609
Coronary artery diseaseEar and labyrinth disorders3/151625/151840/251315/1264912/1518418/19609
Acute myocardial infarctionEar and labyrinth disorders6/151624/151841/251310/1264911/1518421/19609
AppendicitisInfections and infestations5/151624/151840/251313/126497/1518413/19609
DiverticulitisInfections and infestations4/151622/151840/251312/126494/151846/19609
Most frequent other events
Most frequent other events
EventPart A (Blinded): PlaceboPart A (Blinded): mRNA-1273Part B (Open-label): PlaceboPart B (Open-label): Placebo/mRNA-1273Part B (Open-label): mRNA-1273Part C: mRNA-1273 Booster
COVID-19Infections and infestations947/1516292/1518421/2513489/12649650/151844885/19609
Injection site painGeneral disorders165/15162327/151840/2513559/1264945/151842764/19609
FatigueGeneral disorders954/151621078/151846/2513343/12649141/151841515/19609
HeadacheNervous system disorders1046/151621087/151844/2513384/12649200/151841150/19609
Upper respiratory tract infectionInfections and infestations361/15162305/1518418/2513441/12649491/151841017/19609

Baseline characteristics

All randomized participants who received at least 1 dose of treatment.

Age, Continuous
Age, Continuous(years)PlacebomRNA-1273Total
Mean51.3 ± 15.6051.4 ± 15.5051.4 ± 15.55
Sex: Female, Male
Sex: Female, Male(Participants)PlacebomRNA-1273Total
Female7109726314372
Male8057791715974
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlacebomRNA-1273Total
Hispanic or Latino310931216230
Not Hispanic or Latino119211191723838
Unknown or Not Reported136142278
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlacebomRNA-1273Total
Race — White120011203124032
Race — Black or African American153115673098
Race — Asian7396561395
Race — American Indian or Alaska Native121113234
Race — Native Hawaiian or other Pacific Islander323668
Race — Multiracial319319638
Race — Other294299593
Race — Not Reported7497171
Race — Unknown5562117
09

Study locations

100 sites
  • Ascension St. Vincent Birmingham
    Birmingham, Alabama 35205, United States
  • Synexus Clinical Research US, Inc. - Birmingham
    Birmingham, Alabama 35211, United States
  • Hope Research Institute
    Chandler, Arizona 85224, United States
  • Synexus Clinical Research US, Inc. - Phoenix West
    Glendale, Arizona 85306, United States
  • Hope Research Institute
    Peoria, Arizona 85018, United States
  • Hope Research Institute
    Phoenix, Arizona 85018, United States
  • Quality of Life Medical and Research Center
    Tucson, Arizona 85712, United States
  • Baptist Health Center for Clinical Research
    Little Rock, Arkansas 72205, United States
  • Advanced Clinical Research - Rancho Paseo
    Banning, California 92220, United States
  • University of California San Diego
    La Jolla, California 92093, United States
  • eStudySite - La Mesa
    La Mesa, California 91942, United States
  • UCLA Vine Street Clinic CRS
    Los Angeles, California 90038, United States
  • VA Greater Los Angeles Healthcare (veterans only)
    Los Angeles, California 90073, United States
  • Paradigm Clinical Research Institute Inc
    Redding, California 96001, United States
  • Benchmark Research - Sacramento
    Sacramento, California 95864, United States
  • Medical Center For Clinical Research - M3 Wake Research
    San Diego, California 92108, United States
  • University of Colorado Hospital
    Aurora, Colorado 80045, United States
  • Lynn Institute of The Rockies
    Colorado Springs, Colorado 80918, United States
  • George Washington University
    Washington, District of Columbia 20037, United States
  • Accel Research Site
    DeLand, Florida 32720, United States
  • Research Centers of America
    Hollywood, Florida 33024, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Synexus - Optimal Research - Melbourne
    Melbourne, Florida 32934, United States
  • Suncoast Research Group
    Miami, Florida 33135, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Synexus Clinical Research US, Inc. - Orlando
    Orlando, Florida 32806, United States
  • Palm Beach Research Center
    West Palm Beach, Florida 33409, United States
  • Grady Health System
    Atlanta, Georgia 30303, United States
  • Children's Healthcare of Atlanta
    Atlanta, Georgia 30322, United States
  • Hope Clinic of The Emory Vaccine Center
    Decatur, Georgia 30030, United States
  • Meridian Clinical Research
    Savannah, Georgia 31406, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • Synexus Clinical Research US, Inc. - Chicago
    Chicago, Illinois 60602, United States
  • UIC Project WISH CRS
    Chicago, Illinois 60612, United States
  • University of Chicago-Hospital
    Chicago, Illinois 60637, United States
  • Johnson County Clin-Trials
    Lenexa, Kansas 66219, United States
  • Alliance for Multispecialty Research
    Newton, Kansas 67114, United States
  • Alliance for Multispecialty Research- East Wichita
    Wichita, Kansas 67207, United States
  • Meridian Clinical Research
    Baton Rouge, Louisiana 70808, United States
  • Benchmark Research - Metairie
    Metairie, Louisiana 70006, United States
  • University of Maryland School of Medicine
    Baltimore, Maryland 21201, United States
  • Synexus - Optimal Research - Rockville
    Rockville, Maryland 20850, United States
  • Meridian Clinical Research
    Rockville, Maryland 20854, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • MediSync Clinical Research Hattiesburg Clinic
    Petal, Mississippi 39465, United States
  • Saint Louis University
    Saint Louis, Missouri 63104, United States
  • Sundance Clinical Research
    Saint Louis, Missouri 63141, United States
  • Meridian Clinical Research
    Grand Island, Nebraska 68803, United States
  • Meridian Clinical Research
    Norfolk, Nebraska 68701, United States
  • Meridian Clinical Research
    Omaha, Nebraska 68134, United States
  • Clinical Research Center of Nevada
    Las Vegas, Nevada 89104, United States
  • AB Clinical Trials
    Las Vegas, Nevada 89119, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • New Jersey Medical School
    Newark, New Jersey 07103, United States
  • Meridian Clinical Research
    Binghamton, New York 13901, United States
  • Weill Cornell Chelsea - (CRS)
    New York, New York 10010, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Tryon Medical Partners
    Charlotte, North Carolina 28210, United States
  • Carolina Institute for Clinical Research - M3 Wake Research
    Fayetteville, North Carolina 28304, United States
  • M3 Wake Research, Inc - M3 Wake
    Raleigh, North Carolina 27612, United States
  • Trial Management Associates
    Wilmington, North Carolina 28403, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • Synexus Clinical Research US, Inc. - Cincinnati
    Cincinnati, Ohio 45236, United States
  • New Horizons Clinical Research
    Cincinnati, Ohio 45242, United States
  • Cincinnati CRS
    Cincinnati, Ohio 45267, United States
  • Rapid Medical Research Inc
    Cleveland, Ohio 44122, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Crisor
    Medford, Oregon 97504, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • UPMC University Center
    Pittsburgh, Pennsylvania 15213, United States
  • Keystone VitaLink Research
    Anderson, South Carolina 29621, United States
  • Keystone VitaLink Research - Greenville
    Greenville, South Carolina 29615, United States
  • Coastal Carolina Research Center
    Mount Pleasant, South Carolina 29464, United States
  • Keystone VitaLink Research - Spartanburg
    Spartanburg, South Carolina 29303, United States
  • Meridian Clinical Research
    Dakota Dunes, South Dakota 57049, United States
  • WR-ClinSearch
    Chattanooga, Tennessee 37421, United States
  • Alliance for Multispecialty Research
    Knoxville, Tennessee 39720, United States
  • Vanderbilt University Medical Center, Medical Arts Building
    Nashville, Tennessee 37232, United States
  • Vanderbilt University Medical Center, Medical Center North
    Nashville, Tennessee 37232, United States
  • Benchmark Research - Austin
    Austin, Texas 78705, United States
  • Synexus - Optimal Research - Austin
    Austin, Texas 78705, United States
  • Tekton Research
    Austin, Texas 78745, United States
  • Advanced Clinical Research - Be Well MD
    Cedar Park, Texas 78613, United States
  • Global Medical Research - M3 Wake Research
    Dallas, Texas 75224, United States
  • Synexus Clinical Research US, Inc. - Dallas
    Dallas, Texas 75234, United States
  • Benchmark Research - Fort Worth
    Fort Worth, Texas 76135, United States
  • University of Texas Medical Branch at Galveston
    Galveston, Texas 77555, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • DM Clinical Research - Texas Center For Drug Development
    Houston, Texas 77081, United States
  • Laguna Clinical Research
    Laredo, Texas 78041, United States
  • Centex Studies
    McAllen, Texas 78504, United States
  • Benchmark Research - San Angelo
    San Angelo, Texas 76904, United States
  • Clinical Trials of Texas, Inc
    San Antonio, Texas 78229, United States
  • DM Clinical Research
    Tomball, Texas 77375, United States
  • Synexus Clinical Research US, Inc. - Salt Lake City
    Murray, Utah 84123, United States
  • Foothill Family Clinic - North
    Salt Lake City, Utah 84109, United States
  • Foothill Family Clinic-South Clinic
    Salt Lake City, Utah 84121, United States
  • Kaiser Permanente - Seattle
    Seattle, Washington 98101, United States
10

References and documents

Publications

  • Fraiman J, Erviti J, Jones M, Greenland S, Whelan P, Kaplan RM, Doshi P. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. Vaccine. 2022 Sep 22;40(40):5798-5805. doi: 10.1016/j.vaccine.2022.08.036. Epub 2022 Aug 31. PubMed 36055877 ↗
  • Follmann D, Janes HE, Buhule OD, Zhou H, Girard B, Marks K, Kotloff K, Desjardins M, Corey L, Neuzil KM, Miller JM, El Sahly HM, Baden LR. Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial. Ann Intern Med. 2022 Sep;175(9):1258-1265. doi: 10.7326/M22-1300. Epub 2022 Jul 5. PubMed 35785530 ↗
  • El Sahly HM, Baden LR, Essink B, Montefiori D, McDermont A, Rupp R, Lewis M, Swaminathan S, Griffin C, Fragoso V, Miller VE, Girard B, Paila YD, Deng W, Tomassini JE, Paris R, Schodel F, Das R, August A, Leav B, Miller JM, Zhou H, Pajon R; Coronavirus Efficacy (COVE) Study Group. Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial. J Infect Dis. 2022 Nov 11;226(10):1731-1742. doi: 10.1093/infdis/jiac188. PubMed 35535503 ↗
  • Pajon R, Paila YD, Girard B, Dixon G, Kacena K, Baden LR, El Sahly HM, Essink B, Mullane KM, Frank I, Denhan D, Kerwin E, Zhao X, Ding B, Deng W, Tomassini JE, Zhou H, Leav B, Schodel F; COVE Trial Consortium. Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial. Nat Med. 2022 Apr;28(4):823-830. doi: 10.1038/s41591-022-01679-5. Epub 2022 Feb 10. PubMed 35145311 ↗
  • El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, Campbell TB, Clark J, Jackson LA, Fichtenbaum CJ, Zervos M, Rankin B, Eder F, Feldman G, Kennelly C, Han-Conrad L, Levin M, Neuzil KM, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Polakowski L, Mascola JR, Ledgerwood JE, Graham BS, August A, Clouting H, Deng W, Han S, Leav B, Manzo D, Pajon R, Schodel F, Tomassini JE, Zhou H, Miller J; COVE Study Group. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med. 2021 Nov 4;385(19):1774-1785. doi: 10.1056/NEJMoa2113017. Epub 2021 Sep 22. PubMed 34551225 ↗
  • Gilbert PB, Montefiori DC, McDermott A, Fong Y, Benkeser D, Deng W, Zhou H, Houchens CR, Martins K, Jayashankar L, Castellino F, Flach B, Lin BC, O'Connell S, McDanal C, Eaton A, Sarzotti-Kelsoe M, Lu Y, Yu C, Borate B, van der Laan LWP, Hejazi N, Huynh C, Miller J, El Sahly HM, Baden LR, Baron M, De La Cruz L, Gay C, Kalams S, Kelley CF, Kutner M, Andrasik MP, Kublin JG, Corey L, Neuzil KM, Carpp LN, Pajon R, Follmann D, Donis RO, Koup RA. Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. medRxiv [Preprint]. 2021 Aug 15:2021.08.09.21261290. doi: 10.1101/2021.08.09.21261290. PubMed 34401888 ↗
  • Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30. PubMed 33378609 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Dec 2022, 29 months.

Results were first posted in Mar 2024, 1 year 2 months after primary completion.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 29 months is above that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2020
First posted
Jul 14, 2020
StartActual
Jul 27, 2020
Primary completionActual
Dec 29, 2022
CompletionActual
Dec 29, 2022
Results first posted
Mar 21, 2024
Last update
Mar 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04470427
Lead sponsor
ModernaTX, Inc.
Collaborators
Biomedical Advanced Research and Development Authority, National Institute of Allergy and Infectious Diseases (NIAID)
Responsible party
Sponsor
First posted
Jul 14, 2020
Start date
Jul 27, 2020
Primary completion
Dec 29, 2022
Completion
Dec 29, 2022
Results posted
Mar 21, 2024
Last update
Mar 21, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 2019-nCoV Vaccine mRNA-1273

Start the discussion